A sustainable multi-task HPLC-UV method for simultaneous analysis of top neuromodulating agents in diverse pharmaceutical formulations.

Epilepsy is a chronic neurological disease that affects the brain and causes a recurrent seizure. This condition affects a lot of people worldwide making it a global neurological disorder. The first line for managing epilepsy, is the use of Anti-epileptic drugs. Herein, a reliable and ecological chromatographic method was developed, verified and validated for the simultaneous determination of three approved drugs that can be co-administered in many treatment protocols for epilepsy management; Piracetam (PIR), Gabapentin (GBP) and Levetiracetam (LEV). The developed method was founded on high performance liquid chromatography (HPLC-UV). Separation was accomplished using a 5.0 μm particle size, 250 × 4.6 mm Inertsil ODS-3 C column with the UV detection set at 210.0 nm. An isocratic elution system was employed, consisting of a mixture of methanol and water in a ratio of 15:85 (v/v) at ambient temperature. The developed method demonstrated linearity throughout a range of concentration of 30.0-1000.0 µg/mL for GBP and 10.0-100.0 µg/mL for LEV and PIR. The suggested method was optimized and validated following the guidelines stated by the ICH and was utilized for the determination of the aforementioned drugs in their respective pharmaceutical formulation. Moreover, the supremacy of the developed method was further extended for monitoring the in-vitro release profile of the stated drugs and content uniformity of their marketed pharmaceutical formulations. Finally, the ecological impact of the suggested method was monitored, evaluated and compared to the official HPLC ones utilizing newly introduced greenness, blueness and whiteness assessment methods tools.